NetworkNewsBreaks

ThursdayDec 22, 2016 1:47 pm

NetworkNewsBreaks – Inovio (NASDAQ: INO) Releases Early Clinical Results of Zika Vaccine

Inovio Pharmaceuticals (NASDAQ: INO) released results of its DNA-based Zika vaccine (GLS-5700) phase I trial designed to evaluate the safety, tolerability and induction and persistence of Zika specific antibody and T cell responses. In initial testing, Zika-naïve subjects in both low dose and high dose vaccine groups demonstrated Zika antigen-specific antibody responses after one or two vaccinations. The vaccine has been well tolerated and no significant safety concerns have been noted to date. “These early clinical results show that Inovio is on track to rapidly develop Zika countermeasures for this disease that has no currently existing vaccine or treatment. Our…

Continue Reading

ThursdayDec 22, 2016 12:51 pm

NetworkNewsBreaks – Second Sight (NASDAQ: EYES): UK Government Greenlights Funding for Argus II “Bionic Eye” Implants

Second Sight Medical Products (NASDAQ: EYES) has made a groundbreaking achievement after advisors issued a positive recommendation to the UK Government’s healthcare funding authority for specialized services in England. For the first time in the UK, the publicly funded NHS system will fund blind patients with Retinitis Pigmentosa (RP) to receive treatment with Second Sight’s innovative Argus® II Retinal Prosthesis System (Argus II) “bionic eye.” A selective group of severely blind patients with RP will have access to Argus II, the world’s first and only routinely used treatment for severe blindness. The hospitals and Second Sight will provide follow up,…

Continue Reading

ThursdayDec 22, 2016 12:49 pm

NetworkNewsBreaks – Tokai Pharmaceuticals (NASDAQ: TKAI) Trades Higher on Share Purchase Agreement with Otic Pharma

Tokai Pharmaceuticals (NASDAQ: TKAI) shares are up 38% mid-day after the company announced its definitive share purchase agreement with Otic Pharma Ltd., as well as the shareholders of Otic Pharma who will become the majority owners of Tokai. The transaction will result in a NASDAQ-listed company focused on the development and commercialization of products for ear, nose and throat (ENT) disorders. The emerging company will operate under the name OticPharma, Inc., and will be led by current Otic Pharma CEO Gregory J. Flesher. “Over the last several months, Tokai has conducted an extensive review of strategic alternatives aimed at maximizing…

Continue Reading

WednesdayDec 21, 2016 1:58 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on December 21, 2016

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: NTFU 25.71% – News: Enters strategic partnership with JZ Marketing Group PTCO 45.71% – News: Purchased two oil and gas leases in Ohio VBIO 16.55%– News: DEA greenlights cannabinoid pharma development facility ESEA 9.94% – News: Will acquire Hull DY160 from Dayang shipyard SORL 5.79% – News: Increases 2016 FY earnings, sales guidance MSRT 3.44% – News: Appoints new CFO GLBL 3.25% – News: Posts 2015 financial results, files Form 10-K to regain regulatory…

Continue Reading

WednesdayDec 21, 2016 1:16 pm

NetworkNewsBreaks – Calithera Biosciences, Inc. (NASDAQ: CALA), Bristol-Myers Squibb (NYSE: BMY) Collaborate to Assess Combination of Opdivo, CB-839

Calithera Biosciences (NASDAQ: CALA) and Bristol-Myers Squibb (NYSE: BMY) have entered into a clinical trial collaboration to evaluate Bristol-Myers Squibb’s Opdivo in combination with Calithera’s CB-839 in patients with clear cell renal cell carcinoma (ccRCC). Preclinical data suggest that CB-839 – currently in phase 1/2 clinical studies - may enhance the effects of, and reverse tumor resistance to checkpoint inhibitors by altering the immune-suppressive microenvironment and encouraging an anti-tumor immune response. Opdivo is designed to overcome immune suppression. Under the collaboration, Calithera and Bristol-Myers will explore the potential of combining their agents with the goal of achieving improved and continual…

Continue Reading

WednesdayDec 21, 2016 1:13 pm

NetworkNewsBreaks – Moxian, Inc. (NASDAQ: MOXC) Utilizes Key Data to Reach Target Demographics in China

Moxian (NASDAQ: MOXC) is securing a foothold in the O2O (online-to-offline) market in China by paying attention to who is using O2O services, and how active those users are on social media. “Unlike in the U.S. or Europe, where O2O is often considered to be items purchased online and picked up at a store, in China O2O includes a range of categories. O2O in China takes into account travel, accommodation, transport, dinner reservations, medical appointments, and virtually any services that are ordered or booked online but paid for at point of service. With this in mind, who is the primary…

Continue Reading

WednesdayDec 21, 2016 1:11 pm

NetworkNewsBreaks – Sphere 3D (NASDAQ: ANY) Shares Climb After Subsidiary Launches 4TB RDX Cartridges

Shares are up 50% for Sphere 3D (NASDAQ: ANY) following the news of its wholly owned subsidiary, Tandberg Data, releasing its new 4TB RDX® cartridges. The new cartridges fit any RDX disk-based storage system, including Tandberg Data's QuikStor™ and QuikStation™.  The 4TB RDX cartridge is designed for usage in data-intensive environments, such as professional workflow and archiving, hybrid cloud applications and database seeding. The company says it has the highest capacity RDX media on the market today, increasing maximum per cartridge storage by 30 percent. To view the full press release, visit: http://nnw.fm/j8mMz About Tandberg Data Tandberg Data is a…

Continue Reading

TuesdayDec 20, 2016 2:55 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on December 20, 2016

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: OMTL 117.39% – News: Enters acquisition agreement ETST 21.02% – News: Developing multiple new CBD nutraceutical and pharmaceutical products BNTC 13.18%– News: Released positive in vivo model data using the company's technology to treat hepatitis B virus TVIA 9.52% – News: Suspends ingredient supply to Soylent SMDM 9.09% – News: Presenting new products at Consumer Electronics Tradeshow in Las Vegas, January 4-7, 2017 CVSI 8.24% – News: Released statement regarding many MLB stadium’s recent…

Continue Reading

TuesdayDec 20, 2016 2:34 pm

NetworkNewsBreaks – Conatus (NASDAQ: CNAT) Skyrockets on Exclusive Licensing Deal with Novartis (NYSE: NVS)

Conatus Pharmaceuticals (NASDAQ: CNAT) shares are up 141% following the early-morning announcement of an exclusive option, collaboration and license agreement with Novartis (NYSE: NVS) for the global development and commercialization of its first-in-class, orally active pan-caspase inhibitor emricasan. Per the agreement, Conatus will receive $50 million upfront, and is eligible to receive $7 million following the exercise of the license option. Conatus can borrow up to $15 million in the form of convertible promissory notes under an investment agreement with Novartis. Conatus will host a conference call and webcast presentation at 5:30 p.m. ET today. “The option to co-commercialize in…

Continue Reading

TuesdayDec 20, 2016 1:37 pm

NetworkNewsBreaks – OurPet’s Company (OPCO) Sets Sights on Open Market for Interactive Dog Toys

OurPet’s Company (OTCQX: OPCO) recently opened up about the details of its continued growth in the booming non-food pet product industry. With the majority of the company’s success linked to the cat market, OPCO plans to exploit the open market for interactive dog toys. “Approximately 61% of OPCO’s revenue comes from the cat market, mostly toys and accessories together with waste and odor products, while 38% comes from the dog market, mostly feeding and storage products. However, OPCO also sees untouched opportunities in the dog toys area. As with its cat toys, OPCO has put research into the sensations and…

Continue Reading